We are monitoring the impact of COVID-19 on APAC Anti-neoplastic Agents Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 8049
Share on
Share on

Asia-Pacific Anti-neoplastic Agents Market Research Report – Segmented By Product Type, End User & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) – Industry Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 8049
Pages: 145

The size of the Asia Pacific Anti-neoplastic Agents Market is predicted to have a noticeable CAGR during the forecast period.

Factors such as the rising cancer incidence and the demand for cost-effective treatment options are expected to drive the APAC antineoplastic agents market. Anti-neoplastic drug makers have a tremendous opportunity due to the rapid progress in customized medicine. In addition, increasing investment in cancer research by multinational corporations due to rising cancer prevalence is predicted to drive the market for anti-neoplastic drugs over the forecast period. Changes in an individual's DNA are one of the most common causes of such occurrences, resulting in impaired gene activity and, eventually, Cancer.

Furthermore, as the number of people diagnosed with cancer grows, discoveries of advanced and modified technologies are expected to propel the Antineoplastic agents market forward during the forecast period. As a result, the antineoplastic market is expanding at a reasonable rate. In addition, the growing number of low-cost medicines to cure them has fueled the rise of the anti-neoplastic agents market. Chemotherapeutic agents, biological or immunotherapeutic agents, are used in radiotherapies, surgeries, hormone therapies, and other targeted therapies in combination with other drugs, which drives market trends.

Consumers' lifestyles are changing, which means the danger of cancer is rising. This has piqued the interest of numerous pharmaceutical companies to enter the anti-neoplastic agent industry, increasing in the antineoplastic agent market. The APAC anti-neoplastic agents market is also driven by stringent regulations about the safety of drug development procedures and the effectiveness of quality control and quality assurance rules that regulate the pharmaceutical and related industries in this nation.

Anti-neoplastic drugs are costly due to the significant expenses associated with their development. Some customers cannot afford these agents, which is expected to hamper the growth of the antineoplastic agents market. The varied nature of cancer and the high development cost of anti-neoplastic drugs restrict the market's growth. Physicians and researchers face a significant challenge in meeting unmet requirements in treating malignant neoplasms as the number of patients grows. Antineoplastic medicines are frequently employed as first-line therapy for cancer treatment and in conjunction with surgery or radiation therapy.

This research report on the APAC Anti-neoplastic Agents market has been segmented and sub-segmented into the following categories.

By Product:

  • Chemotherapeutic Agents
  • Biological Agents   
  • Personalized Medicine  

By End Users:

  • Hospitals 
  • Clinics        
  • Cancer Rehabilitation Centers            
  • Ambulatory Surgical Centers           

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Over the forecast period, the Asia-Pacific segment is expected to increase at the fastest rate. Factors contributing to this segment's growth include an increase in infectious and cancer cases as the population grows and rising GDPs in developing countries like India and China, which result in increased investment in research and state-of-the-art healthcare infrastructure. In addition, with new cases of neoplasms being reported in the region, the antineoplastic market is expected to grow rapidly. In the near future, the Antineoplastic Agents Market is expected to increase due to the rising demand for cost-effective medicines for treating neoplasms.

KEY MARKET PLAYERS:

Some of the major companies dominating the market by their products and services include Aspen Global Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Pvt. Ltd., Merc & Co., Inc., Pfize Inc., Hoffmann-La Roche Ltd., Amgen Inc., Bristol-Myers Squibb Company, Baxter Healthcare Corporation, Boehringer Ingelheim GmbH, Accord Healthcare, Inc., Genentech, Inc., Lundbeck LLC, AbbVie Inc.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Product                        

                                5.1.1 Introduction           

                                5.1.2 Chemotherapeutic agent 

                                5.1.3 Biological agents   

                                5.1.4 Personalied medicine         

                                5.1.5  Y-o-Y Growth Analysis, By Product              

                                5.1.6  Market Attractiveness Analysis, By Product            

                                5.1.7  Market Share Analysis, By Product              

                5.2 End user                      

                                5.2.1 Introduction           

                                5.2.2 Hospitals  

                                5.2.3 Clinics        

                                5.2.4 Cancer rehabilitaion centers            

                                5.2.5 Ambulatory surgical centers            

                                5.2.6 Y-o-Y Growth Analysis, By end user             

                                5.2.7 Market Attractiveness Analysis, By end user           

                                5.2.8 Market Share Analysis, By end user             

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Product

                                                6.1.3.3 By end user

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Product

                                                6.1.4.3 By end user

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Product

                                                6.1.5.3 By end user

                6.2 China                             

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea                               

                6.6 Australia                      

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Hoffmann-La Roche Ltd                        

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Amgen Inc.                 

                8.3 Bristol-Myers Squibb Company                         

                8.4 Baxter Healthcare Corporation                          

                8.5 Boehringer Ingelheim GmbH                              

                8.6 Aspen Global Inc.                     

                8.7 Bayer AG                     

                8.8 Teva pharmaceutical Industries Ltd.                

                8.9 Johnson & Johnson Pvt. Ltd.                               

                8.10 Accord Healthcare, Inc.                       

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of Product Type, by End user along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

                                                                                                                          

  1. Asia Pacific Anti-neoplastic agents Market, By Product, From 2021 to 2026 (USD Billion)
  2. Asia Pacific Chemotherapeutic agents Market, By Region, From 2021 to 2026 (USD Billion)
  3. Asia Pacific Biological agents Market, By Region, From 2021 to 2026 (USD Billion)
  4. Asia Pacific Personalised medicine Market, By Region, From 2021 to 2026 (USD Billion)
  5. Asia Pacific Anti-neoplastic agents Market, By End user, From 2021 to 2026 (USD Billion)
  6. Asia Pacific Hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  7. Asia Pacific Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  8. Asia Pacific Cancer rehabilitation centers Market, By Region, From 2021 to 2026 (USD Billion)
  9. Asia Pacific Ambulatory surgical centers Market, By Region, From 2021 to 2026 (USD Billion)
  10. Japan Anti-neoplastic agents Market, By Product, From 2021 to 2026 (USD Billion)
  11. Japan Anti-neoplastic agents Market, By End user, From 2021 to 2026 (USD Billion)
  12. China Anti-neoplastic agents Market, By Product, From 2021 to 2026 (USD Billion)
  13. China Anti-neoplastic agents Market, By End user, From 2021 to 2026 (USD Billion)
  14. India Anti-neoplastic agents Market, By Product, From 2021 to 2026 (USD Billion)
  15. India Anti-neoplastic agents Market, By End user, From 2021 to 2026 (USD Billion)
  16. Australia Anti-neoplastic agents Market, By Product, From 2021 to 2026 (USD Billion)
  17. Australia Anti-neoplastic agents Market, By End user, From 2021 to 2026 (USD Billion)
  18. South Korea Anti-neoplastic agents Market, By Product, From 2021 to 2026 (USD Billion)
  19. South Korea Anti-neoplastic agents Market, By End user, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample